China SXT Pharmaceuticals Inc (NASDAQ:SXTC) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 278,900 shares, a decline of 7.7% from the June 30th total of 302,200 shares. Based on an average trading volume of 54,900 shares, the short-interest ratio is presently 5.1 days. Currently, 3.3% of the shares of the company are short sold.
Institutional investors have recently modified their holdings of the stock. Spark Investment Management LLC bought a new position in shares of China SXT Pharmaceuticals during the first quarter valued at about $94,000. Invesco Ltd. bought a new position in shares of China SXT Pharmaceuticals during the second quarter valued at about $88,000. Finally, Jane Street Group LLC bought a new position in shares of China SXT Pharmaceuticals during the second quarter valued at about $72,000. 0.16% of the stock is owned by institutional investors.
Shares of SXTC stock traded down $0.24 during mid-day trading on Thursday, reaching $2.56. 15,100 shares of the company’s stock traded hands, compared to its average volume of 178,104. The firm has a 50 day moving average price of $2.85 and a two-hundred day moving average price of $4.64. China SXT Pharmaceuticals has a 12 month low of $1.97 and a 12 month high of $23.35.
China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine tablets in China. It provides oral prescription drugs and supplements under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company offers its products to pharmaceutical distributors, pharmaceutical companies, pharmacies, and hospitals through sales representatives.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.